RE: Towards the end of Q1 we had16 Jun 2025 09:58
23 January 2025
THG PLC
Fourth quarter trading statement for the period ended 31 December 2024
Successful completion of the Demerger of THG Ingenuity, leaving THG PLC as a global, cash generative, health & wellness consumer brands group
FY 2024 performance in-line with expectations
Gross leverage materially reduced, c. £550m[1] year-end cash and available facilities
Continued confidence in THG Beauty and an improved start to the year in THG Nutrition online and offline channels
Strategic update
· THG Ingenuity Demerger successfully completed, leaving THG PLC as a global, cash generative, health & wellness consumer brands group comprising THG Beauty and THG Nutrition ("RemainCo").
· Transfer to the equity shares (commercial companies) ("ESCC") category of the Official List now concluded (6 January 2025), making the company eligible for index inclusion.
Outlook and guidance
· During the second half we continued to see improving underlying trends within Nutrition particularly in the UK, alongside promotional discipline supporting increased order profitability and margin expansion in Beauty. Coupled with a strong Q4 for Ingenuity, FY 2024 adjusted EBITDA is expected to be in-line with the consensus range excluding discontinued categories.
· RemainCo is expected to deliver mid-single digit revenue growth in FY 2025, given continued confidence in prestige beauty demand across our key markets, and a return to growth in Nutrition, evidenced by a much-improved start to the year across online and offline channels.
· Ahead of the Demerger, FY 2025 adjusted EBITDA assumptions were based upon:
o a leaner, more efficient cost base and improved inventory profile;
o continued execution of the Beauty strategy;
o a gradual reduction from the current historic whey price highs; and
o another strong year for THG Ingenuity, supported by a pipeline underpinning adjusted EBITDA of £40m to £45m.
· Whilst whey price reductions are anticipated to be second half weighted, new global manufacturing volumes of high concentrate whey protein will enter the market through Q1 2025, providing optimism of a more normalised commodity market ahead.
· Depending on the outcome of the recent UK VAT ruling for protein powders, annual adjusted EBITDA upside could be in the region of c. £10m.
· Over the medium term, revenue growth of mid to high-single digit is anticipated, with adjusted EBITDA margins consistent with historical levels (for Beauty and Nutrition), and significantly improved free cash flow.
· Specifically, capital expenditure will reduce to c. £20m pa (FY 2024 pre Demerger guidance: £100m to £110m) and cash lease costs will reduce to c. £22m pa.
· Future cash generation will facilitate a measured reduction in gross and net leverage, with RemainCo targeting continued progression to a neut